- /
- Supported exchanges
- / IL
- / 0O14.IL
MERCK Kommanditgesellschaft auf Aktien (0O14 IL) stock market data APIs
MERCK Kommanditgesellschaft auf Aktien Financial Data Overview
Merck KGaA operates as a science and technology company in Germany. The company's Life Science segment offers a range of products, including reagents, consumable, devices, instruments, software, and services for scientific discovery, as well as provides lab water instruments, consumables and services, microbiology and biomonitoring, products, test assays, analytical reagents, and flow cytometry kits and instruments for pharma and biotech, industrial and testing, academics and government, and diagnostic sectors. Its Healthcare segment designs and develops medicines and intelligent devices for treatment of various therapeutics, such as oncology, neurology and immunology, endocrinology, and general medicines. The company's Electronic segment provides semiconductor solutions, such as semiconductor materials, delivery systems and services, and intermolecular services for semiconductor and polymer removal chemistries applications; and display solutions comprising liquid crystals, OLED and quantum materials, reactive mesogens, photoresist materials, smart antenna, and dynamic liquid crystal glazing products, as well as offers liviFlex, a flexible platform, which offers a range of display materials. This segment also provides surface solution, such as cosmetics, effect pigments, and functional solutions; architecture solutions, including switchable windows; and automotive solutions. In addition, it has strategic alliances with Pfizer Inc. and GlaxoSmihKline plc to develop and commercialize active ingredients in immune-oncology; in-licensing agreement with Debiopharm International SA for developing drug candidates for the treatment of head and neck cancer; and out-licensing agreement with MoonLake Immunotherapeutics AG for developing a drug candidate for the treatment of inflammatory diseases. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get MERCK Kommanditgesellschaft auf Aktien data using free add-ons & libraries
Get MERCK Kommanditgesellschaft auf Aktien Fundamental Data
MERCK Kommanditgesellschaft auf Aktien Fundamental data includes:
- Net Revenue: 22 061 M
- EBITDA: 6 227 M
- Earnings Per Share: 7
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-13
- EPS/Forecast: 2.21
Get MERCK Kommanditgesellschaft auf Aktien End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MERCK Kommanditgesellschaft auf Aktien News
New
Does Merck KGaA’s Rebound Reflect Its True Value After AI Partnership And CEO Change News
Wondering if Merck KGaA is a bargain hiding in plain sight or a value trap at €118.85? This article unpacks what the market is really pricing in. The stock has slipped 0.2% over the last week, but i...
Latent Labs Announces Latent-X2: AI-Generated Antibodies With Drug-Like Developability and Low Ex Vivo Immunogenicity
LONDON & SAN FRANCISCO, December 16, 2025--(BUSINESS WIRE)--Today, Latent Labs announces Latent-X2, a frontier AI model that can design drug-like biologics without iteration. Drug hunters can use Late...
Immunome, A Top 3% Stock, Just Delivered A 'Knockout' To Merck KGaA
Top-notch biotech stock Immunome rocketed Monday after the company's treatment for desmoid tumors appeared to top an approved drug. Continue Reading
Lateral Flow Assay Components Market to Hit USD 486.2 Million by 2030: Rising Prevalence of Infectious Diseases Drives Growth
Company Logo The global lateral flow assay (LFA) components market is poised for significant growth, projected to reach USD 486.2 million by 2030 from USD 392.4 million in 2025, with a CAGR of 4.4%. ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.